Cargando…
Endogenous cardiotonic steroids and cardiovascular disease, where to next?
Ever since British Physician William Withering first described the use of foxglove extract for treatment of patients with congestive heart failure in 1785, cardiotonic steroids have been used clinically to treat heart failure and more recently atrial fibrillation. Due to their ability to bind and in...
Autor principal: | Pavlovic, Davor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031694/ https://www.ncbi.nlm.nih.gov/pubmed/31896530 http://dx.doi.org/10.1016/j.ceca.2019.102156 |
Ejemplares similares
-
Endogenous Mammalian Cardiotonic Steroids—A New Cardiovascular Risk Factor?—A Mini-Review
por: Słabiak-Błaż, Natalia, et al.
Publicado: (2021) -
Cardiotonic Steroids as Modulators of Neuroinflammation
por: Orellana, Ana Maria, et al.
Publicado: (2016) -
Na,K-ATPase as a target for endogenous cardiotonic steroids: What's the evidence?
por: Orlov, Sergei N., et al.
Publicado: (2020) -
Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids
por: Ren, Junwei, et al.
Publicado: (2022) -
The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension
por: Keppel, Martin H., et al.
Publicado: (2019)